Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate staphylococcus epidermidis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2781-2786

  Garcia de la Maria C ^a   Marco, F ^a   Armero, Y ^a   Soy, D ^a   Moreno, A ^a   Del Rio A ^a   Almela, M ^a   Cervera, C ^a   Ninot, S ^a   Falces, C ^a   Mestres, C A ^a   Gatell, J M ^a   De Jimenez Anta M T ^a   Miro J M ^a   Malucelli, C ^a   Pare J C ^a   Cartana R ^a   Azqueta, M ^a   Sitges, M ^a   Heras, T ^a   Pomar, J L ^a   Ramirez J ^a   Ribalta, T ^a   Brunet, M ^a   De Lazzari, E ^a   more..

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; VANCOMYCIN; GLYCOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENDOCARDITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS EPIDERMIDIS; ANIMAL; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; PENICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; DAPTOMYCIN; ENDOCARDITIS; GLYCOPEPTIDES; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN;

EID: 77953823382     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01011-09     Document Type: Article

References (29)

1. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, Jr., A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, and K. A. Taubert. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394-e434.
2. Biavasco, F., C. Vignaroli, and P. E. Varaldo. 2000. Glycopeptide resistance in coagulase-negative staphylococci. Eur. J. Clin. Microbiol. Infect. Dis. 19:403-417.
3. Cervera, C., M. Almela, J. A. Martinez-Martinez, A. Moreno, and J. M. Miro. 2009. Risk factors and management of Gram-positive bacteraemia. Int. J. Antimicrob. Agents 34(Suppl. 4):S26-S30.
4. Cha, R., and M. J. Rybak. 2003. Daptomycin against multiple drug-resistant Staphylococcus and Enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn. Microbiol. Infect. Dis. 47:539-546.
5. Chambers, S. T. 2005. Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators. Intern. Med. J. 35(Suppl. 2):S63-S71.
6. Chu, V. H., J. M. Miro, B. Hoen, C. H. Cabell, P. A. Pappas, P. Jones, M. E. Stryjewski, I. Anguera, S. Braun, P. Munoz, P. Commerford, P. Tornos, J. Francis, M. Oyonarte, C. Selton-Suty, A. J. Morris, G. Habib, B. Almirante, D. J. Sexton, G. R. Corey, and V. G. Fowler, Jr. 2009. Coagulase-negative staphylococcal prosthetic valve endocarditis - a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study. Heart 95:570-576.
7. Chu, V. H., C. W. Woods, J. M. Miro, B. Hoen, C. H. Cabell, P. A. Pappas, J. Federspiel, E. Athan, M. E. Stryjewski, F. Nacinovich, F. Marco, D. P. Levine, T. S. Elliott, C. Q. Fortes, P. Tornos, D. L. Gordon, R. Utili, F. Delahaye, G. R. Corey, and V. G. Fowler, Jr. 2008. Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin. Infect. Dis. 46:232-242.
8. Cubist Pharmaceuticals. 2008. Cubicin (daptomycin for injection). Prescribing information. Cubist Pharmaceuticals, Inc., Lexington, MA.
9. del Rio, A., I. Anguera, J. M. Miro, L. Mont, V. G. Fowler, Jr., M. Azqueta, and C. A. Mestres. 2003. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest 124:1451-1459.
10. Eliopoulos, G., and R. Moellering. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian. (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins, Co., Baltimore, MD.
11. Forouzesh, A., P. A. Moise, and G. Sakoulas. 2009. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob. Agents Chemother. 53:483-486.
12. Fowler, V. G., Jr., H. W. Boucher, G. R. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Tally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Bernstein, C. S. Price, G. N. Forrest, G. Fatkenheuer, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, and S. E. Cosgrove. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
13. Garrett, D. O., E. Jochimsen, K. Murfitt, B. Hill, S. McAllister, P. Nelson, R. V. Spera, R. K. Sall, F. C. Tenover, J. Johnston, B. Zimmer, and W. R. Jarvis. 1999. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect. Control Hosp. Epidemiol. 20:167-170.
14. Garrison, P. K., and L. R. Freedman. 1970. Experimental endocarditis. I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale J. Biol. Med. 42:394-410.
15. Hidayat, L. K., D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144.
16. Hope, R., D. M. Livermore, G. Brick, M. Lillie, and R. Reynolds. 2008. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. J. Antimicrob. Chemother. 62(Suppl. 2):ii65-ii74.
17. Isenberg, H. D. 2004. Clinical microbiology procedures handbook. ASM Press, Washington, DC.
18. John, J. F., and A. M. Harvin. 2007. History and evolution of antibiotic resistance in coagulase-negative staphylococci: susceptibility profiles of new anti-staphylococcal agents. Ther. Clin. Risk Manag. 3:1143-1152.
19. LaPlante, K. L., and M. J. Rybak. 2004. Clinical glycopeptide- intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Microbiol. Infect. Dis. 50:125-130.
20. Marco, F., C. G. de la Maria, Y. Armero, E. Amat, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. M. Gatell, M. T. Jimenez de Anta, and J. M. Miro. 2008. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2538-2543.
21. Miro, J. M., C. Garcia-de-la-Maria, Y. Armero, E. de-Lazzari, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. M. Gatell, M. T. Jimenezde-Anta, and F. Marco. 2007. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2373-2377.
22. Moise, P. A., A. Forrest, S. M. Bhavnani, M. C. Birmingham, and J. J. Schentag. 2000. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am. J. Health Syst. Pharm. 57(Suppl. 2):S4-S9.
23. Murdoch, D. R., G. R. Corey, B. Hoen, J. M. Miro, V. G. Fowler, Jr., A. S. Bayer, A. W. Karchmer, L. Olaison, P. A. Pappas, P. Moreillon, S. T. Chambers, V. H. Chu, V. Falco, D. J. Holland, P. Jones, J. L. Klein, N. J. Raymond, K. M. Read, M. F. Tripodi, R. Utili, A. Wang, C. W. Woods, and C. H. Cabell. 2009. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch. Intern. Med. 169:463-473.
24. NCCLS/CLSI. 2006. Performance standards for antimicrobial disk susceptibility tests; approved standard, 9th ed. M2-A9. NCCLS/CLSI, Wayne, PA.
25. Rybak, M., B. Lomaestro, J. C. Rotschafer, R. Moellering, Jr., W. Craig, M. Billeter, J. R. Dalovisio, and D. P. Levine. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
26. Rybak, M. J., E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin- dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066.
27. Sakoulas, G., Y. Golan, K. C. Lamp, L. V. Friedrich, and R. Russo. 2007. Daptomycin in the treatment of bacteremia. Am. J. Med. 120:S21-S27.
28. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
29. Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.